Liver X receptor marks the spot

Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in metastatic melanoma.¹

The group, led by The Rockefeller University assistant professor Sohail Tavazoie, came upon the nuclear hormone receptor as a melanoma target while studying the effect of apolipoprotein E (APOE) on cancer metastasis...